About MM Biotech

A foundational technology engine for AI, polysaccharides and microbiome innovation

MM Biotech develops AI-enabled R&D infrastructure for natural polysaccharides and the microbiome. Through AI4Glyco, proprietary polysaccharide resource databases, high-fidelity SynCom validation and standardized industrial delivery, we support B2B partners from candidate screening and validation through commercialization.

MM Biotech team at an innovation program

University of MacauIncubated at the University of Macau and rooted in Hengqin-Macao collaborative innovation

Core Team

A core team spanning scientific strategy, technology development, commercialization and delivery

Chief scientists, a chief business advisor and leaders across R&D, technology and operations connect scientific validation, platform development, client delivery and industrial translation.

Chief Scientist

Lixian Liang

With longstanding expertise in traditional Chinese medicine and the broader health sector, she brings extensive experience in TCM pharmacology, precision therapeutics and the translation of research outcomes. She provides scientific evaluation and professional guidance for the company's research strategy, product innovation and research translation priorities.

Professor, Faculty of Health Sciences, University of Macau
National Young Qihuang Scholar
Member of the Macao Economic Development Council and Science and Technology Council

Chief Scientist

Kan Ding

With extensive experience in the structure and function of traditional Chinese medicine polysaccharides, their mechanisms of action and innovative carbohydrate drug research, he provides scientific review and guidance on the company's polysaccharide technology roadmap, key scientific questions and functional translation.

Executive Vice President, CAS Zhongshan Institute for Drug Discovery
Researcher, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Recipient of the National Science Fund for Distinguished Young Scholars

Chief Business Advisor

Canhui Lan

He leads platform strategy and industrialization planning. Drawing on more than 20 years of serial entrepreneurship and corporate management experience, he connects scientific, industry and expert resources to align research outcomes with market needs and accelerate industrial translation.

Chair and President, R Institute
Chair, Ningbo R-Institute of Science Communication
Lecture Professor, Evergreen Scholar Program, Wuhan Polytechnic University

Ziming Wang

Co-founder & CEO

He leads the company's strategy and operations, advancing the AI4Glyco platform, industry partnerships and B2B commercialization while connecting scientific innovation, product translation and industry needs.

Corporate strategy and operations
AI4Glyco platform development
Industry partnerships and commercialization

Shuyun Jiang

Technical Director

She leads the development of the polysaccharide resource library and polysaccharide-microbiome technology system, coordinating data standards, validation workflows and technical implementation to strengthen the platform's technical foundation.

Polysaccharide resource development
Technology system development
Patent strategy and technical delivery

Wing Kai Leong

R&D Director

He leads project design, experimental coordination and schedule management for enterprise R&D engagements, translating client needs into deliverable research outcomes.

Client requirement translation
Custom R&D program management
R&D deliverables

Yining Chen

Administrative Director

She oversees day-to-day operations and administration, coordinating projects, internal and external resources and delivery workflows to ensure efficient and orderly execution.

Operations and administration
Project and resource coordination
Delivery workflow assurance

Company Development

From University of Macau incubation to AI4Glyco platform commercialization

Company development continues across University of Macau incubation, platform capability building, product translation and Hengqin-Macau industrial collaboration.

2024.08

Entered the University of Macau Innovation and Entrepreneurship Centre

Built the company foundation for AI, polysaccharide science and microbiome innovation within the University of Macau and Hengqin-Macau innovation corridor.

2024-2025

Supported by UM CIE and Macau incubation programs

Entered entrepreneurship, big health acceleration, university-industry incubation and enterprise R&D support programs in Macau.

2025.04

Software copyright obtained for the Wuxi project

Continued to convert AI4Glyco platform capabilities into software assets for future SaaS/DaaS and reporting systems.

2025.05

Two polysaccharide skincare products launched in Macau

Extended polysaccharide function research into functional skincare, validating ingredient screening, formulation and commercialization expression.

2025.12

HSITP project approved in the Hong Kong-Shenzhen innovation corridor

Expanded into the Greater Bay Area innovation network while preparing follow-up innovation program resources.

2026.01

Hengqin subsidiary established and industrial collaboration signed

Completed the Hengqin company setup and signed a collaboration agreement with Shanghai Sine Microecology.

2026.03-06

Major R&D projects and partner collaborations advanced

Advanced Hengqin major R&D projects, probiotic and multinational ingredient collaborations, and the Qin Research Institute Voyage Program.

2028-2029

Continued alignment with Macau innovation funds and industrial space

Plans to deepen access to Macau innovation funds, technology park resources and Hengqin-Macau industrial collaboration.

Macau Innovation Story

Cultivated by UM, incubated in Macau, benchmarked in Macau and exported outward

MM Biotech is a representative company incubated by the University of Macau, aligned with Macau's economic diversification, AI high-tech development and traditional Chinese medicine / big health strategy.

Built from the University of Macau Innovation and Entrepreneurship Centre and Macau technology park ecosystem.

Uses AI4Glyco to translate Macau's polysaccharide, microbiome and TCM resources into industrial R&D capabilities.

Continues to connect with Macau innovation funds, technology park space and Hengqin-Macau industrial resources.

Macau technology research industrial park — Macau technology park

Macau innovation island — Hengqin-Macau innovation

CIK sharing cooperation signing ceremony — Innovation collaboration signing

Macau innovation exchange event — Macau innovation exchange

Honors & IP

Intellectual Property and R&D Portfolio

Selected records reflecting the company's R&D and intellectual-property development. Ownership, scope and validity are subject to the corresponding official documents.

MM Biotech R&D certificate 1 — R&D and intellectual-property record 01

MM Biotech R&D certificate 2 — R&D and intellectual-property record 02

MM Biotech R&D certificate 3 — R&D and intellectual-property record 03

MM Biotech R&D certificate 4 — R&D and intellectual-property record 04

Partners

Industrial, clinical and research partners

The collaboration network spans industrial translation, clinical resources and research institutions, supporting AI4Glyco from underlying science to product delivery.

Industrial Partners

Covers polysaccharide ingredients, probiotics, synthetic biology, equipment platforms, functional food and industrial translation ecosystems.

Clinical Partners

Connects TCM hospitals, integrated hospitals and regional clinical resources for efficacy validation and translational pathways.

Research Partners

Deepens platform capabilities through University of Macau, TCM quality research, microbiology, drug discovery and Greater Bay Area university networks.